Dernières nouvelles pour 180 Life Sciences (NASDAQ:ATNF) Stock

180 Life Sciences

180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.

Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) has outperformed the market over the past 5 years by 3.89% on an annualized basis producing an average annual return of 18.68%. Currently, Ulta Beauty has a market capitalization of $21.47 billion. 
Buying $100 In ULTA: If an investor had bought $100 of ULTA stock 5 years ago, it would be worth $228.61 today based on a price of $477.79 for ULTA at the time of writing.
<h3>Ulta Beauty's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751577312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

ULTA

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

In a major political victory, President Donald Trump secured the first legislative triumph of his second term, as House Republicans passed his <a href="https://www.benzinga.com/news/financing/25/07/46215975/trumps-big-beautiful-bill-offers-seniors-a-6000-bonus-tax-deduction-heres-how-you-qualify-for-the-benefit">sweeping domestic agenda bill</a> on Thursday, just ahead of the July 4 holiday.
Dubbed the "One Big, Beautiful Bill," the $3.3 trillion package includes a mix of tax cuts, military and border security boosts, and the steepest federal safety net reductions in decades, CNN <a href="https://www.cnn.com/2025/07/03/politics/trump-agenda-passed-congress">reports</a>.
The Senate had approved the legislation earlier in the week, and despite opposition from two House Republicans, the bill cleared both chambers largely along party lines. GOP leaders — Speaker Mike Johnson and Senate Majority Leader John Thune — overcame internal resistance to deliver on Trump's top campaign promises.
The bill makes permanent the 2017 individual tax cuts and doubles the standard deduction, a move the Tax Policy Center says will save the average filer about $2,900 in 2026. Seniors will temporarily get an added $6,000 deduction, but Trump's campaign pledge to end Social Security <a href="https://www.benzinga.com/news/financing/25/07/46215083/how-trumps-big-beautiful-bill-impacts-snap-medicaid-taxes-and-student-loans">taxes was dropped.</a>
Also Read: <a href="https://www.benzinga.com/news/politics/25/07/46237506/trump-says-jerome-powell-should-resign-immediately-after-fhfa-director-alleges-fed-chair-lied-about-2-5-billion-renovation-plan">Trump Says Jerome Powell Should &#8216;Resign Immediately&#8217; After FHFA Director Alleges Fed Chair Lied About $2.5 Billion Renovation Plan</a>
At the heart of the package are aggressive changes to Medicaid and SNAP. The bill imposes new work requirements and paperwork hurdles that the Congressional Budget Office estimates will cause 12 million people to lose Medicaid coverage, CBS News <a href="https://www.cbsnews.com/news/comparing-medicaid-cuts-house-senate-trump-big-beautiful-bill/">reports</a>. States will shoulder more program costs and face penalties for high payment errors.
Regarding education, the bill caps graduate loans and phases out popular programs, including Grad PLUS and subsidized loans. Forgiveness options shrink, and new borrowing limits will hit middle-class families the hardest.
Yet, the bill also introduces a pilot program called "Trump Accounts." Every baby born from 2025 through 2028 will receive a $1,000 stock market account seeded by the federal government, with parents allowed to contribute up to $5,000 annually.
Democrats, with Minority Leader Hakeem Jeffries at the helm, criticized the bill as favoring the wealthy while placing undue burdens on vulnerable communities.
Jeffries vowed to make the bill the centerpiece of 2026 midterm campaigns, citing $295 billion in SNAP cuts and a $1 trillion Medicaid rollback.
Despite the backlash, Trump and GOP leaders are already celebrating what they view as a defining legislative moment — a bet that the benefits will outweigh the political risks come election season.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/topics/25/07/46252465/cybertruck-dreams-shatter-as-musks-250k-goal-unravels">Cybertruck Dreams Shatter As Musk&#8217;s 250K Goal Unravels</a></li>
</ul>
Photo: Shutterstock

Politics

Trump's $3.3 Trillion Bill Passes: Will Vulnerable Americans Pay The Price?

<h3>Gainers</h3>
<ul>
<li>EpicQuest Education Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEIQ#NASDAQ">EEIQ</a>) stock increased by 13.9% to $0.55 during Thursday's after-market session. The company's market cap stands at $6.5 million. </li>
<li>Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) stock moved upwards by 6.06% to $0.81. The company's market cap stands at $82.7 million. </li>
<li>INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) stock rose 5.73% to $1.29. The market value of their outstanding shares is at $11.1 million. </li>
<li>Crown Crafts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWS#NASDAQ">CRWS</a>) shares moved upwards by 5.08% to $3.1. The market value of their outstanding shares is at $30.5 million. </li>
<li>Twin Hospitality Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWNP#NASDAQ">TWNP</a>) shares increased by 4.98% to $4.84. The market value of their outstanding shares is at $264.7 million. </li>
<li>Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) stock moved upwards by 4.85% to $3.67. The company's market cap stands at $44.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fenbo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEBO#NASDAQ">FEBO</a>) shares declined by 9.3% to $0.98 during Thursday's after-market session. The market value of their outstanding shares is at $10.3 million. </li>
<li>Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) stock fell 6.14% to $1.53. The company's market cap stands at $89.5 million. </li>
<li>Lazydays Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) shares fell 5.93% to $0.23. The market value of their outstanding shares is at $27.0 million. </li>
<li>Jinxin Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMI#NASDAQ">NAMI</a>) shares fell 5.41% to $1.05. The company's market cap stands at $72.6 million. </li>
<li>OneWater Marine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) shares decreased by 5.0% to $14.25. The company's market cap stands at $217.6 million. </li>
<li>American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) shares declined by 5.0% to $10.09. The company's market cap stands at $134.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AOUT

CRWS

EEIQ

FEBO

FOSL

GORV

INEO

ISPO

NAMI

ONEW

PRPL

TWNP

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock increased by 13.8% to $4.46 during Thursday's after-market session. The company's market cap stands at $13.1 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares increased by 11.11% to $0.45. The company's market cap stands at $20.7 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares rose 10.29% to $6.43. The company's market cap stands at $100.6 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock rose 9.85% to $0.7. The company's market cap stands at $74.9 million. </li>
<li>Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) stock rose 9.17% to $14.76. The market value of their outstanding shares is at $613.0 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares moved upwards by 9.02% to $1.45. The company's market cap stands at $78.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock declined by 16.6% to $2.36 during Thursday's after-market session. The company's market cap stands at $5.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 14.97% to $19.55. The company's market cap stands at $5.1 billion. As per the news, the H1 earnings report came out 3 days ago. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock decreased by 9.09% to $10.11. The company's market cap stands at $6.1 million. </li>
<li>Coherus Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares declined by 8.62% to $0.74. The company's market cap stands at $92.1 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares decreased by 6.38% to $0.87. The market value of their outstanding shares is at $2.8 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares decreased by 5.87% to $0.71. The market value of their outstanding shares is at $13.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBNX

CGTX

CHRS

INDP

LIXT

NTHI

PROK

SONN

TRIB

WINT

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) stock increased by 9.4% to $2.57 during Thursday's after-market session. The company's market cap stands at $5.6 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) shares moved upwards by 7.92% to $0.72. The company's market cap stands at $6.4 million. </li>
<li>GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) stock rose 7.81% to $27.3. The market value of their outstanding shares is at $3.4 billion. </li>
<li>Eshallgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHGO#NASDAQ">EHGO</a>) stock moved upwards by 7.31% to $0.88. The market value of their outstanding shares is at $22.9 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock moved upwards by 6.68% to $3.51. The market value of their outstanding shares is at $109.5 million. </li>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) stock rose 5.91% to $0.68. The company's market cap stands at $21.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) shares decreased by 8.0% to $6.99 during Thursday's after-market session. The company's market cap stands at $128.3 million. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) shares fell 6.28% to $0.63. The company's market cap stands at $9.9 million. </li>
<li>MingZhu Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) stock decreased by 5.4% to $0.96. The company's market cap stands at $75.1 million. </li>
<li>Controladora Vuela (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLRS#NYSE">VLRS</a>) stock decreased by 5.2% to $4.56. The market value of their outstanding shares is at $554.3 million. </li>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) shares decreased by 4.97% to $14.92. The market value of their outstanding shares is at $1.4 billion. </li>
<li>Highway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIHO#NASDAQ">HIHO</a>) stock decreased by 4.94% to $1.54. The company's market cap stands at $7.2 million. As per the news, the Q4 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EHGO

GLXG

HIHO

HUHU

IPDN

NEOV

VLRS

YGMZ

12 Industrials Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Youxin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YAAS#NASDAQ">YAAS</a>) stock increased by 11.0% to $0.51 during Thursday's after-market session. The company's market cap stands at $15.2 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock moved upwards by 6.69% to $0.43. The market value of their outstanding shares is at $16.7 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) shares rose 5.91% to $2.15. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) shares rose 5.17% to $4.88. The market value of their outstanding shares is at $6.9 million. </li>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) shares increased by 4.6% to $1.59. The market value of their outstanding shares is at $22.8 million. </li>
<li>MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) shares rose 4.58% to $0.68. The company's market cap stands at $21.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) shares declined by 10.4% to $121.01 during Thursday's after-market session. The market value of their outstanding shares is at $354.7 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares decreased by 8.02% to $0.39. The market value of their outstanding shares is at $11.3 million. </li>
<li>Bridgeline Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLIN#NASDAQ">BLIN</a>) stock fell 6.09% to $1.39. The company's market cap stands at $17.1 million. </li>
<li>Locafy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) shares declined by 5.65% to $5.35. The company's market cap stands at $7.6 million. </li>
<li>Forward Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORD#NASDAQ">FORD</a>) shares decreased by 5.13% to $7.4. The company's market cap stands at $7.8 million. </li>
<li>Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) shares decreased by 5.0% to $2.47. The market value of their outstanding shares is at $76.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLIN

BMNR

BNAI

CMBM

CMTL

FORD

GREE

LCFY

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

OBLG

SVRE

YAAS

12 Information Technology Stocks Moving In Thursday's After-Market Session

Throughout the last three months, 7 analysts have evaluated Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.71, along with a high estimate of $22.00 and a low estimate of $13.00. A decline of 18.56% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1751576451_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Chemours. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Chemours. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chemours compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Chemours's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Chemours's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Chemours analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Chemours: A Closer Look</h2>
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
<h3>A Deep Dive into Chemours's Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Chemours showcased positive performance, achieving a revenue growth rate of 0.44% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Chemours's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.29% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Chemours's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.68%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Chemours's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.05%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Chemours's debt-to-equity ratio stands notably higher than the industry average, reaching 7.57. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Chemours's Future

Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) has outperformed the market over the past 5 years by 5.6% on an annualized basis producing an average annual return of 20.39%. Currently, Simon Property Group has a market capitalization of $54.40 billion. 
Buying $1000 In SPG: If an investor had bought $1000 of SPG stock 5 years ago, it would be worth $2,418.98 today based on a price of $166.74 for SPG at the time of writing.
<h3>Simon Property Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751576425_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Simon Property Group 5 Years Ago Would Be Worth This Much Today

In the current session, the stock is trading at $57.95, after a 1.12% increase. Over the past month, Fidelity National Finl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) stock increased by 7.37%, and in the past year, by 20.56%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1751576417_0.png" alt="Past Year Chart" />

<h3>A Look at Fidelity National Finl P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 23.37 in the Insurance industry, Fidelity National Finl Inc. has a lower P/E ratio of 14.22. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751576417_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Fidelity National Finl Inc's Price Over Earnings

LRHC

Trading Halt: Halted at 4:50:00 p.m. ET - Trading Halt: Halt News Pending

LVLU

FLYE

Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) has outperformed the market over the past 20 years by 6.94% on an annualized basis producing an average annual return of 15.44%. Currently, Equinix has a market capitalization of $76.60 billion. 
Buying $1000 In EQIX: If an investor had bought $1000 of EQIX stock 20 years ago, it would be worth $17,641.78 today based on a price of $787.00 for EQIX at the time of writing.
<h3>Equinix's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751575513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EQIX

Here's How Much $1000 Invested In Equinix 20 Years Ago Would Be Worth Today

On June 30, 2025, the Board of Directors of Sharps Technology, Inc. (the "Company") appointed Paul Danner to serve as the Company's Executive Chairman, replacing Soren Christiansen, who was a non-executive Chairman.
&nbsp;
In connection with Mr. Danner's appointment and resulting change in independence status, the Board appointed Timothy Ruemler to serve as Chairman of the Audit Committee. Additionally, the Board appointed Soren Christiansen to fill Mr. Danner's seat on the Compensation Committee.

Management

STSS

Sharps Technology Appoints Paul Danner As Executive Chairman

On July 1, 2025, Beam Therapeutics Inc. (the "Company") entered into an Agreement and Plan of Merger pursuant to which it acquired an early-stage life sciences company (the "Agreement"). As consideration for the acquisition, the Company agreed to issue to the shareholders of the company (i) 403,128 shares of the Company's common stock, par value $0.01 per share (the "Common Stock") as an upfront payment (the "Upfront Shares") and (ii) up to an aggregate of $89,000,000 in potential additional payments upon the achievement of certain development, clinical and commercial milestones, which milestone payments may be made in cash or in shares of Common Stock (the "Milestone Shares") in the Company's sole discretion. Based on the closing price of the Common Stock of $17.01 per share on June 30, 2025, the maximum number of Milestone Shares issuable pursuant to the Agreement is 5,232,216 shares; however, the exact number of Milestone Shares cannot be determined at this time, and the Company intends to file an amendment to this Form 8-K to disclose the exact number of Milestone Shares issued, if any. The issuance of the Upfront Shares and any Milestone Shares that the Company elects to issue in satisfaction of milestone payments will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws. Based in part upon the representations of the shareholders of the company in the Agreement, the Company has relied on the exemption from the registration requirements of the Securities Act under Section 4(a)(2) thereof for a transaction by an issuer not involving any public offering.&nbsp;

BEAM

Beam Therapeutics Enters Agreement To Acquire Early-Stage Life Sciences Company For 403,128 Upfront Shares And Up To $89M In Milestone Payments

Preliminary Q2 2025 Operating Results
Emeren is also providing its preliminary financial updates for the second quarter of 2025. Based on currently available information, the Company expects the following:
<ul>
<li>A non-cash impairment of no less than $20 million on global property, plant, and equipment (PPE), primarily reflecting an updated fair value assessment of certain power station assets in accordance with U.S. GAAP.</li>
</ul>

Guidance

Emeren Expects A Non-Cash Impairment Of No Less Than $20M On Global Property, Plant, And Equipment

Investor Kevin O&#8217;Leary, who just finished taping &#8220;a big chunk&#8221; of Season 17 of &#8220;Shark Tank,&#8221; says it&#8217;s shaping up to be one of the most exciting yet.&nbsp;
It&#8217;s also the first without longtime shark Mark Cuban, who has <a href="https://www.benzinga.com/general/entertainment/25/05/45472538/mark-cuban-bids-farewell-to-shark-tank-how-to-watch-finale-and-whats-next-for-hit-show">announced</a> he would be leaving the show after Season 16. His absence marks a major shift, but the energy on set remains high, according to O&#8217;Leary.
<h2 class="wp-block-heading">Big Companies, Bigger Problems</h2>
&#8220;The market for venture capital has dried up,&#8221; O&#8217;Leary said in a recent <a href="https://x.com/kevinolearytv/status/1938382234798715257">post on X</a>. &#8220;It reminds me of 2008, 2009.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
According to O&#8217;Leary, even large companies with solid sales are now turning to &#8220;Shark Tank&#8221; to <a href="https://www.benzinga.com/personal-finance/25/06/46034399/startup-investing-used-to-be-for-millionaires-not-anymore">raise money</a> and get global exposure. &#8220;They just can&#8217;t raise money and so they&#8217;re coming to the &#8216;Shark Tank&#8217; for two things: to get that global exposure, it&#8217;s in 154 countries, and of course to seek capital,&#8221; he said.
O&#8217;Leary added that the show has been attracting a wider range of businesses, including those already generating serious revenue. &#8220;Every year seems to be the same. The deals get bigger and the companies get larger.&#8221;
He said this season is packed with innovation, including healthy food alternatives, tech, and even artificial intelligence. &#8220;I keep saying this every year: this is the best year ever,&#8221; he said. &#8220;The number of innovation, companies, like just huge. Really interesting.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a>&nbsp;
<h2 class="wp-block-heading">His Advice for Entrepreneurs? Just Start</h2>
In another recent <a href="https://x.com/kevinolearytv/status/1938345869071298659">post</a>, O&#8217;Leary addressed the uncertainty of today's economy, especially with crypto booming, interest rates fluctuating, and geopolitical risks piling up. His advice to new entrepreneurs is simple: just start.
&#8220;More than half the time [successful companies are founded] in times of extreme stress or volatility,&#8221; he said. &#8220;It really doesn&#8217;t have a good or bad time to start — it&#8217;s just start is what you have to do.&#8221;
He also pointed out that failure is a constant part of entrepreneurship. &#8220;The <a href="https://www.benzinga.com/news/topics/25/06/45772125/90-of-startups-fail-heres-whats-going-wrong">majority of the startups fail</a> anyways, and they always have since the 1950s when they&#8217;ve been tracking venture capital,&#8221; he noted.
See Also: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
Still, he said, the journey often pays off. &#8220;The nature of the journey is exactly that — it&#8217;s never a destination. It&#8217;s a journey,&#8221; O&#8217;Leary said.
For many entrepreneurs, he added, the payoff comes later in the form of a buyout, going public, or getting acquired. &#8220;And then they just get back on the road and continue the journey.&#8221;
Read Next: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Image: Shutterstock

Kevin O'Leary Says The Venture Capital Market Has 'Dried Up' Like In 2008. Now Even Big Companies Are Coming On 'Shark Tank' For Funding

Quantum computing stocks had a big week with a completed offering and bullish analyst coverage<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening"> of several stocks.&nbsp;</a>
Here&#8217;s a look at the highlights, lowlights and news catalysts in the quantum computing sector.
<h3 class="wp-block-heading">D-Wave Quantum &#8211; QBTS&nbsp;</h3>
D-Wave Quantum, Inc. (NYSE: QBTS) announced on Tuesday that <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening" target="_blank" rel="noopener">it had </a><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening">successfully </a>sold $400 million of its common stock, completing the offering at an average price of $15.18 per share.
On Wednesday, Cantor Fitzgerald analyst Troy Jensen <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46232263/d-wave-surges-1326-whats-driving-quantum-computings-newest-star">initiated coverage</a> on D-Wave Quantum with an Overweight rating and a $20 price target. 
Read Next:<a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/07/46245952/metas-growth-sizzles-but-wait-for-a-pullback-before-buying-in?utm_source=articleShare"> Meta&#8217;s Growth Sizzles, But Wait For A Pullback Before Buying In</a>
Jensen said the company is in the very early innings of commercializing its technology and is positioned to capture 15% of the quantum hardware, software and services market by 2035.&nbsp;&nbsp;
D-Wave Quantum stock has gained 16% over the past five days.&nbsp;&nbsp;
<h3 class="wp-block-heading">Rigetti Computing &#8211; RGTI&nbsp;</h3>
Cantor&#8217;s Jensen also<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46230597/quantum-computings-dark-horse-rigetti-stands-at-the-edge-of-greatness"> initiated coverage</a> on Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) with an Overweight rating and a bullish $15 price target.
The analyst noted that after challenging years in 2022 and 2023, Rigetti's share price has rallied since late 2024, increasing by approximately 1,008% over the last 52 weeks.
He also applauded Rigetti's partnership with Quanta Computer and sees the collaboration helping to accelerate the development and commercialization of superconducting quantum computing.&nbsp;
<h3 class="wp-block-heading">IonQ&nbsp;&#8211; IONQ</h3>
IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares rallied about 11% this week. The stock also received a Buy rating<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46229237/cash-rich-ionq-to-capture-20-of-quantum-market-by-2035-analyst"> from Cantor</a> and a $45 price forecast. 
Jensen pointed to IonQ's strong financial position, noting that the company ended the first quarter of 2025 with nearly $700 million in cash following a $373 million equity raise.
<h3 class="wp-block-heading">Quantum Computing &#8211; QUBT</h3>
QUBT: The Cantor analyst initiated coverage on Quantum Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) with a Neutral rating and a $15 price target, well below the stock's current $20 levels. However, the stock remained strong with gains of 67.5% over the past month and over 4,600% in the past year. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46236537/openai-says-tokens-are-not-equity-no-partnership-with-robinhood-musk-says-ai-companys-equity-is-fake?utm_source=articleShare">OpenAI Says Tokens Are Not Equity, No Partnership With Robinhood: Musk Says AI Company&#8217;s Equity &#8216;Is Fake&#8217;</a></li>
</ul>
Image: Shutterstock

Initiation

Tech

IONQ

QBTS

QUBT

RGTI

Quantum Stock Watch: Bullish Analyst Coverage On IonQ, D-Wave, Rigetti Computing

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 10 years by 7.87% on an annualized basis producing an average annual return of 19.69%. Currently, Autodesk has a market capitalization of $67.39 billion. 
Buying $1000 In ADSK: If an investor had bought $1000 of ADSK stock 10 years ago, it would be worth $5,942.20 today based on a price of $315.00 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751574617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

Here's How Much $1000 Invested In Autodesk 10 Years Ago Would Be Worth Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 60.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 22.01% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 16.32% at $1.04</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 14.50% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 8.70% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 8.18% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Growth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 7.62% at $1.28</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 7.10% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 5.31% at $0.31</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.58% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 25.00% at $0.0009</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 13.04% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 8.29% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 7.12% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 6.40% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 6.40% at $0.86</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed down 4.46% at $12.35</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

BBRRF

BLGVF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

FFNTF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

NWVCF

OILFF

TLRY

UGRO

YCBD

ZDPY

Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 3, 2025

Press Releases

180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform

Elray Resources Announces Strategic Sale of Crypto iGaming Technology

180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration

180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

Offerings

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

180 Life Sciences Corp. Announces Share Repurchase

Legal

180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction

Biotech

180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets

Comments

180 Life Sciences

Actualités

Dernières nouvelles pour 180 Life Sciences (NASDAQ:ATNF) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL